AstraZeneca Plc (NASDAQ:AZN) released high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 ...

Ahead of the 10-year anniversary of Tagrisso’s initial FDA approval this fall, AstraZeneca has debuted the first ...

Subjects in the trial received 80mg of Tagrisso daily in oral tablet form, combined with a chemotherapy regimen.

AstraZeneca announces positive results from FLAURA2 phase III trial of Tagrisso plus chemotherapy to treat EGFR-mutated advanced lung cancer: Cambridge, UK Tuesday, July 22, 2025, ...

AstraZeneca is raising its defenses against Johnson & Johnson in a fierce competition in EGFR-mutated non-small cell lung cancer. | Following an FDA approval last year based on a tumor progression ...

AstraZeneca (LSE:AZN) recently announced positive developments regarding TAGRISSO®'s survival benefits in treating non-small ...

AstraZeneca ( AZN) said it is investing $50 billion in U.S. manufacturing by 2030, following the lead of big pharma peers ...

AstraZeneca Plc. announced on Monday that it plans to invest $50 billion in the U.S. by 2030, with a focus on expanding drug ...

Tagrisso is AstraZeneca’s top-selling cancer drug, and in the second quarter of 2024, it generated around $1.6 billion in sales. The approval follows the FDA’s Priority Review based on results ...

AstraZeneca’s (AZN) Tagrisso has been recommended for approval in the European Union for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer, or NSCLC ...

(RTTNews) - British drug major AstraZeneca PLC (AZN, AZN.L) announced Thursday that its Tagrisso (osimertinib) has been approved in the US for the ...

AstraZeneca's <AZN.L> top-selling drug Tagrisso has been shown to slow the spread of a certain type of lung cancer to the brain when diagnosed at an early stage, the British drugmaker said on ...